Visual Abstract Summary: SURMOUNT-3 Phase 3 Trial Objective: To evaluate the efficacy and safety of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, in achieving additional weight loss in adults with overweight or obesity who … Read More
Masonry Blog + Sidebar
HEAL-HOA Trial: volunteering among lonely older adults
Objective: To assess the effects of structured social volunteering over 12 months on loneliness among older adults during the COVID-19 pandemic. Study Design: Findings: 📉 Volunteering significantly reduced loneliness at 6 months (T2) compared to control: ⚠️ Most benefits were … Read More
TIME Trial: Evening versus morning dosing of usual antihypertensives
TIME StudyHypertension Treatment in Morning versus Evening Objective:To determine whether evening dosing of antihypertensive medication improves major cardiovascular outcomes compared to morning dosing in patients with hypertension. Study Design: Participants: Primary Endpoint: Results: Conclusion:Evening dosing of antihypertensive medication did not … Read More
POST-TNK Trial: Intra-Arterial Tenecteplase in Acute Stroke
Visual Summary of POST-TNK Trial Objective:To evaluate the efficacy and safety of intra-arterial tenecteplase in patients with large vessel occlusion stroke achieving near-complete to complete reperfusion after EVT. Design & Participants: Interventions:Patients were randomized into two groups: Primary Outcome:Freedom from … Read More
STOPDAPT-2 ACS: Clopidogrel Monotherapy after ACS
Visual Abstract Summary for the STOPDAPT-2 ACS Trial Question Is 1–2 months of dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy noninferior to 12 months of DAPT with aspirin and clopidogrel in patients with acute coronary syndromes (ACS)? Design Key … Read More
ARIES-HM3 Trial: Aspirin + VKA in LVAD
Visual Abstract Summary for the ARIES-HM3 Trial Question Can aspirin be safely excluded from an antithrombotic regimen, including a vitamin K antagonist (VKA), in patients with a fully magnetically levitated LVAD, and does this reduce nonsurgical bleeding complications? Design Key … Read More
REVA Trial: Comparing Spontaneous-Breathing Trials with PSV vs. T-Piece
The REVA trial, published in the New England Journal of Medicine in 2022, addresses a critical question in the management of mechanically ventilated patients: Which strategy for spontaneous breathing trials (SBTs)—Pressure-Support Ventilation (PSV) or a T-piece—offers better outcomes? Objective of … Read More
CAMMS223 Trial: Alemtuzumab vs. Interferon B1a in Early Multiple Sclerosis
Published in the New England Journal of Medicine (2008), the CAMMS223 trial provides critical insights into the efficacy of Alemtuzumab compared to Interferon Beta-1a in patients with early, relapsing-remitting multiple sclerosis (RRMS). This phase 2, randomized, blinded study highlights the … Read More
ATTENTION Trial: Endovascular Treatment for Acute Basilar-Artery Occlusion
Published in the New England Journal of Medicine (2022), the ATTENTION Trial is a landmark study exploring the efficacy and safety of endovascular treatment (EVT) for patients with acute basilar artery occlusion (BAO). Here’s an in-depth look at the findings … Read More
ATHENA-HF Trial: High-Dose Spironolactone in Acute Heart Failure
The ATHENA-HF trial, published in JAMA Cardiology in 2017, evaluated the efficacy and safety of high-dose spironolactone in patients with acute heart failure (AHF). This was a double-blind, placebo-controlled randomized clinical trial, aiming to assess whether high-dose spironolactone could significantly … Read More